

Dreieich, 28 March 2022

290,000 €: Biotest donates blood coagulation drug for young Ukrainian refugees

In the meantime, about 270,000 people, mostly women and children, have arrived in Germany from Ukraine and have thus managed to escape the terror of war. While the vast majority of these refugees are now safe, a few are still threatened, namely by their disease! Patients with hemophilia A ("bleeding disorder") have a congenital deficiency of clotting factor VIII (factor 8) and are constantly at risk of internal bleeding. Therefore, they need a clotting factor medication at regular intervals to compensate for the lack of the vital blood protein.

On 8 March, some refugee haemophilia patients arrived in Duisburg and needed treatment. Since the official procurement of the expensive coagulation factor drugs requires a lot of bureaucratic effort for approval by the cost units due to the high costs, we received a request from the Duisburg-based non-profit organisation "Deutsche Bluthilfe e.V." to quickly provide coagulation factor VIII as a donation on the same day. After record-breakingly fast internal approval, we were able to send a total of 446,000 units of our Factor VIII drug Haemoctin with an equivalent value of € 290,000 to Duisburg as early as 9 March. Not only do the refugees in Duisburg benefit from the coagulation concentrates, the medications are also distributed to other hemophilia treatment centers in Germany and to Lviv in Ukraine.

"I am pleased that the treatment of my "new" patients has been secured for the time being thanks to the rapid assistance provided by Biotest," emphasized Dr. Susan Halimeh, a physician at Deutsche Bluthilfe. (4th from left).

